V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 260010191 | 260006416 | 1.82 | null | Curative (C) | 2017-02-11 | 2017-03-19 | CHLORAMBUCIL + OBINUTUZUMAB | N | N | 260005100 | CISPLATIN + ETOPOSIDE |
| 260010192 | 260006416 | 1.7 | 84.3 | Not known (9) | 2017-12-18 | 2017-12-27 | Cisplatin + Etoposide (3 day) | N | N | 260005100 | CISPLATIN + ETOPOSIDE |
| 260010193 | 260006417 | null | 69 | Disease modification (D) | 2017-04-01 | 2017-04-28 | BLEOMYCIN + CARBOPLATIN + CISPLATIN + VINCRISTINE | N | N | 260006340 | CARBOPLATIN + VINORELBINE |
| 260010194 | 260006418 | null | 77.75 | Disease modification (D) | 2018-10-10 | 2018-10-15 | BLEOMYCIN + VINCRISTINE | 02 | N | 260006543 | BLEOMYCIN + CARBOPLATIN + CISPLATIN + ETOPOSIDE + VINCRISTINE |
| 260010195 | 260006419 | 1.8 | 94.2 | Curative (C) | null | 2016-11-22 | PEMBROLIZUMAB | N | N | 260006709 | BLEOMYCIN + CISPLATIN + VINCRISTINE |
| 260010196 | 260006419 | null | 46.6 | Curative (C) | 2018-03-06 | 2018-03-07 | Cyclophosphamide High Dose | 02 | null | 260006709 | RITUXIMAB |
| 260010197 | 260015758 | 1.79 | 77 | Curative (C) | 2018-08-16 | 2018-12-26 | BLEOMYCIN + CARBOPLATIN + CISPLATIN + VINCRISTINE | Y | N | 260007133 | CISPLATIN + ETOPOSIDE + IFOSFAMIDE |
| 260010198 | 260006420 | 1.74 | 64.6 | null | 2018-12-15 | 2018-12-27 | EP | N | N | 260007145 | CISPLATIN + ETOPOSIDE |
| 260010199 | 260006421 | 1.6 | 94.7 | Curative (C) | 2016-05-08 | 2016-05-13 | BLEOMYCIN + CARBOPLATIN + CISPLATIN + VINCRISTINE | 02 | N | 260007208 | CISPLATIN + ETOPOSIDE |
| 260010200 | 260006421 | null | null | Disease modification (D) | 2017-04-02 | 2017-04-15 | STS Rhabdomyosarcoma RMS 2005 VA | 02 | N | 260007208 | EP |
| 260010201 | 260006422 | 1.68 | 92.6 | Adjuvant (A) | 2014-02-15 | 2014-03-09 | Rituximab | N | N | 260007421 | CARBOPLATIN + PACLITAXEL |
| 260010202 | 260006423 | 1.6 | 48.9 | Curative (C) | 2013-12-26 | 2014-01-08 | BLEOMYCIN + VINCRISTINE | 2 | N | 260007562 | RITUXIMAB |
| 260010203 | 260012506 | 1.8 | null | Curative (C) | 2017-07-11 | 2017-07-14 | CISPLATIN + FLUOROURACIL + RT | N | N | 260007709 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE |
| 260010204 | 260012506 | null | null | Curative (C) | 2016-09-11 | 2016-09-11 | BLEOMYCIN + CARBOPLATIN + CISPLATIN + VINCRISTINE | N | N | 260007709 | CISPLATIN + ETOPOSIDE |
| 260010205 | 260006424 | 1.73 | 70 | Adjuvant (A) | 2014-11-04 | 2014-11-04 | Cisplatin | 02 | N | 260007814 | TEMOZOLOMIDE + RT |
| 260010206 | 260006425 | null | 73.5 | Not known (9) | 2014-02-16 | 2014-02-16 | 111 Trial (formerly BEP 111) | 2 | N | 260007854 | CISPLATIN + ETOPOSIDE |
| 260010207 | 260012507 | 1.7 | null | Disease modification (D) | 2019-07-25 | 2019-07-31 | Carboplatin + Etoposide IV 3 day | 2 | N | 260008106 | TIP |
| 260010208 | 260012507 | 1.85 | 67.7 | Palliative (P) | 2017-01-28 | 2017-02-10 | EP | 2 | N | 260008106 | CISPLATIN + ETOPOSIDE |
| 260010209 | 260006426 | 1.75 | 108.2 | Curative (C) | 2018-12-26 | 2019-01-21 | GemCarbo Days 1+8 | N | Y | 260008946 | EP |
| 260010210 | 260012508 | 1.63 | 69.7 | Palliative (P) | 2018-02-18 | 2018-02-18 | Cisplatin + Etoposide (5 day) | 01 | N | 260008957 | CISPLATIN + ETOPOSIDE |
| 260010211 | 260006427 | 1.67 | 114 | Curative (C) | 2017-11-16 | 2017-12-07 | 111 Trial (formerly BEP 111) | 2 | N | 260009565 | TIP |
| 260010212 | 260012509 | null | 56.9 | null | 2016-03-13 | 2016-04-06 | Rituximab | N | N | 260009956 | FEC |
| 260010213 | 260012509 | 1.58 | 82 | Adjuvant (A) | 2018-12-11 | 2018-12-12 | Chlorambucil | 2 | N | 260009956 | PACLITAXEL |
| 260010214 | 260006428 | null | null | null | 2019-08-14 | 2019-08-15 | CISPLATIN + ETOPOSIDE | 02 | null | 260010652 | TIP |
| 260010215 | 260006429 | 1.8 | 106.4 | Not known (9) | 2016-07-17 | 2016-07-18 | Rituximab (Maintenance) | N | N | 260010715 | RITUXIMAB |
| 260010216 | 260012510 | 1.85 | 107 | Disease modification (D) | null | 2018-05-31 | EP | N | N | 260010775 | CISPLATIN + ETOPOSIDE |
| 260010217 | 260012510 | 1.7 | 64 | Adjuvant (A) | 2017-03-27 | 2017-04-03 | CISPLATIN + ETOPOSIDE | 01 | N | 260010775 | EP |
| 260010218 | 260006430 | 1.62 | 77.5 | Curative (C) | 2016-04-27 | 2016-05-10 | Capecitabine 35days + RT | N | N | 260014181 | RITUXIMAB |
| 260010219 | 260006430 | null | 75.9 | Palliative (P) | 2018-01-19 | 2018-01-19 | Cisplatin + Etoposide (3 day) | 2 | N | 260014181 | CISPLATIN + ETOPOSIDE |
| 260010220 | 260006430 | 1.71 | 77 | Curative (C) | 2015-08-02 | 2015-08-23 | Cisplatin + Etoposide (5 day) | N | N | 260014181 | CISPLATIN |
| 260010221 | 260006431 | 1.9 | 80.7 | Neo-adjuvant (N) | 2018-06-23 | 2018-07-20 | 111 Trial (formerly BEP 111) | N | N | 260015253 | RITUXIMAB |
| 260010222 | 260006432 | null | null | Palliative (P) | null | 2018-07-01 | Carboplatin + Paclitaxel (3 weekly) | N | N | 260015391 | CARBOPLATIN + PEMETREXED |
| 260010223 | 260006432 | 1.64 | 67.35 | Disease modification (D) | 2019-01-19 | 2019-02-01 | FEC 100 | N | N | 260015391 | RITUXIMAB |
| 260010224 | 260006432 | 1.75 | 50.8 | Curative (C) | 2017-03-11 | 2017-04-05 | Cisplatin + Etoposide (5 day) | N | N | 260015391 | CISPLATIN + ETOPOSIDE |
| 260010225 | 260017500 | 1.76 | 0 | Disease modification (D) | 2013-08-10 | 2013-08-15 | BLEOMYCIN + CARBOPLATIN + CISPLATIN + VINCRISTINE | N | N | 260015465 | BLEOMYCIN + VINCRISTINE |
| 260010226 | 260006433 | 1.7 | 73 | Adjuvant (A) | 2017-03-28 | 2017-03-28 | Rituximab | 02 | N | 260015970 | ABVD |
| 260010227 | 260006434 | 1.83 | 81.8 | Palliative (P) | null | 2017-08-16 | Rituximab (Maintenance) | null | null | 260017117 | CISPLATIN + ETOPOSIDE |
| 260010228 | 260012513 | 1.64 | 77 | Adjuvant (A) | 2017-09-23 | 2017-10-01 | Carboplatin 21day + Paclitaxel 7day | N | N | 260017408 | RITUXIMAB |
| 260010229 | 260012513 | 1.71 | 102.3 | null | 2016-01-09 | 2016-01-22 | Carboplatin + Etoposide IV 3 day | 02 | null | 260017408 | NOT MATCHED |
| 260010230 | 260006435 | null | 108 | Palliative (P) | 2014-08-09 | 2014-08-09 | Rituximab | 02 | N | 260017605 | RITUXIMAB |
| 260010231 | 260012514 | 1.91 | 100 | Adjuvant (A) | 2013-11-03 | 2013-11-10 | Carboplatin + Etoposide IV 3 day | 2 | N | 260017719 | BLEOMYCIN + CISPLATIN + ETOPOSIDE + PACLITAXEL |
| 260010232 | 260006436 | 1.71 | 74.5 | Disease modification (D) | 2017-10-20 | 2017-11-08 | EP | N | N | 260018193 | CISPLATIN + VINORELBINE |
| 260010233 | 260006436 | 1.69 | 74 | Curative (C) | 2019-09-07 | 2019-09-13 | Cisplatin + Etoposide (5 day) | 2 | Y | 260018193 | CISPLATIN + ETOPOSIDE |
| 260010234 | 260006437 | 1.72 | 118.8 | Curative (C) | 2017-10-11 | 2017-10-12 | CISPLATIN + ETOPOSIDE + IFOSFAMIDE | 02 | null | 260018270 | CISPLATIN + ETOPOSIDE |
| 260010235 | 260012516 | null | 102.65 | Palliative (P) | 2019-06-14 | 2019-06-13 | ETOPOSIDE + RITUXIMAB | 02 | N | 260018703 | RITUXIMAB |
| 260010236 | 260006438 | 1.65 | 131.4 | Palliative (P) | 2018-01-10 | 2018-01-24 | Cyclophosphamide + Docetaxel | N | N | 260018978 | RITUXIMAB |
| 260010237 | 260006438 | 1.65 | null | Disease modification (D) | 2017-02-08 | 2017-02-16 | BOP | N | N | 260018978 | EP |
| 260010238 | 260006439 | 1.68 | 70 | Curative (C) | 2016-12-22 | 2016-12-30 | Rituximab | null | N | 260020285 | ETOPOSIDE + RITUXIMAB |
| 260010239 | 260006439 | 1.66 | 80 | Disease modification (D) | 2019-10-21 | 2019-11-04 | EP | N | N | 260020285 | CISPLATIN + ETOPOSIDE |
| 260010240 | 260006440 | 1.7 | 92.4 | Disease modification (D) | 2015-03-31 | 2015-04-26 | Cisplatin + Etoposide (3 day) | N | N | 260022289 | RITUXIMAB |